DE3837203C2 - - Google Patents
Info
- Publication number
- DE3837203C2 DE3837203C2 DE3837203A DE3837203A DE3837203C2 DE 3837203 C2 DE3837203 C2 DE 3837203C2 DE 3837203 A DE3837203 A DE 3837203A DE 3837203 A DE3837203 A DE 3837203A DE 3837203 C2 DE3837203 C2 DE 3837203C2
- Authority
- DE
- Germany
- Prior art keywords
- poly
- nucleotides
- phosphorylase
- polymerization
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000006116 polymerization reaction Methods 0.000 claims description 17
- 101001066878 Homo sapiens Polyribonucleotide nucleotidyltransferase 1, mitochondrial Proteins 0.000 claims description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- 102000002681 Polyribonucleotide nucleotidyltransferase Human genes 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 8
- 230000009089 cytolysis Effects 0.000 claims description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 239000012506 Sephacryl® Substances 0.000 claims description 3
- 229920002684 Sepharose Polymers 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229920005654 Sephadex Polymers 0.000 claims description 2
- 239000012507 Sephadex™ Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 102000009097 Phosphorylases Human genes 0.000 claims 2
- 108010073135 Phosphorylases Proteins 0.000 claims 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims 1
- 108091034057 RNA (poly(A)) Proteins 0.000 claims 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 claims 1
- FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims 1
- 229950006790 adenosine phosphate Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000001698 pyrogenic effect Effects 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241001522878 Escherichia coli B Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- MXZRMHIULZDAKC-UHFFFAOYSA-L ammonium magnesium phosphate Chemical compound [NH4+].[Mg+2].[O-]P([O-])([O-])=O MXZRMHIULZDAKC-UHFFFAOYSA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- -1 nucleoside diphosphates Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012985 polymerization agent Substances 0.000 description 1
- 230000027317 positive regulation of immune response Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/814—Enzyme separation or purification
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/814—Enzyme separation or purification
- Y10S435/815—Enzyme separation or purification by sorption
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB878725606A GB8725606D0 (en) | 1987-11-02 | 1987-11-02 | Preparation polynucleotides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3837203A1 DE3837203A1 (de) | 1989-05-11 |
| DE3837203C2 true DE3837203C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1991-08-08 |
Family
ID=10626275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3837203A Granted DE3837203A1 (de) | 1987-11-02 | 1988-11-02 | Polynucleotide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
Country Status (29)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9108085D0 (en) * | 1991-04-16 | 1991-06-05 | Scras | Complexes of polyadenylic acid with polyuridylic acid |
| TW589189B (en) * | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| EP2258712A3 (en) * | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
| EP1582584A4 (en) * | 2002-12-26 | 2006-05-31 | Nippon Shinyaku Co Ltd | PROCESS FOR PRODUCING PNPASE |
| US20050164260A1 (en) * | 2003-12-30 | 2005-07-28 | Sigma-Aldrich Co. | Rapid preparation of nucleic acids by enzymatic digestion |
| EP2281043B1 (en) | 2008-04-25 | 2013-03-13 | Innate Pharma | Improved tlr3 agonist compositions |
| WO2012092540A1 (en) * | 2010-12-30 | 2012-07-05 | Ibis Biosciences, Inc. | Methods for the synthesis of polyadenylic acid |
| CA3165709A1 (en) * | 2020-01-24 | 2021-07-29 | Thomas K. EQUELS | Therapeutic double stranded rna and methods for producing the same |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU6012A1 (ru) * | 1927-04-04 | 1928-07-31 | Л.С. Кравцов | Горизонтальный вод ной двигатель с поворотными лопаст ми |
| JPS4940954B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1970-02-16 | 1974-11-06 | ||
| DE2056081A1 (en) * | 1970-11-14 | 1972-06-22 | Pabst Brewing Company, Milwaukee, Wis. (V.StA.) | Poly nucleotides prepn |
| IL37076A (en) * | 1971-06-16 | 1974-05-16 | Littauer U | A method for stepwise synthesis of oligoribonucleotides of defined sequence using 2'(3')-o-acyl-nucleoside diphosphates and polynucleotide phosphorylase |
| JPS524633B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1972-07-21 | 1977-02-05 | ||
| GB1435571A (en) * | 1973-04-02 | 1976-05-12 | Searle & Co | Polynucleotides |
| DE2319495C2 (de) * | 1973-04-17 | 1985-01-10 | Yeda Research And Development Co., Ltd., Rehovot | Verfahren zum selektiven, reversiblen Binden von Biomolekülen an ein Adsorbens in einer chromatographischen Säule |
| FR2252350A1 (en) * | 1973-11-22 | 1975-06-20 | Choay Sa | Polynucleotide phosphorylase - extraction from E coli, fixation on sepharose, and use in preparing polynucleotides |
| JPS50107187A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1974-02-08 | 1975-08-23 | ||
| US4006059A (en) * | 1974-07-29 | 1977-02-01 | Purdue Research Foundation | Hydrophobic noncovalent binding of proteins to support materials |
| US4000098A (en) * | 1974-08-16 | 1976-12-28 | Palo Alto Medical Research Foundation | Separation of proteins by hydrophobic adsorption |
| SU601287A1 (ru) * | 1976-05-12 | 1978-04-05 | Предприятие П/Я М-5043 | Способ получени полирибонуклеотидов |
| US4075195A (en) * | 1976-08-31 | 1978-02-21 | Kraft, Inc. | Debittered protein product and method for manufacture |
| SU619508A1 (ru) * | 1976-12-07 | 1978-08-15 | Предприятие П/Я Г-4740 | Способ получени полинуклеотидов, обладающих полирибонуклеотидфосфорилазной активностью |
| JPS5922518B2 (ja) * | 1977-03-09 | 1984-05-26 | 三菱化学株式会社 | ポリグアニル酸の製造方法 |
| JPS5618597A (en) * | 1979-07-23 | 1981-02-21 | Mitsubishi Chem Ind Ltd | Production of oligonucleotide |
| US4379843A (en) * | 1981-01-26 | 1983-04-12 | Peter Cashion | Immobilization of polynucleotides and polypeptides with tritylated polysaccharides |
| US4617376A (en) * | 1985-07-01 | 1986-10-14 | Eli Lilly And Company | Process for recovering glucagon from pancreas glands |
| US4771128A (en) * | 1986-10-10 | 1988-09-13 | Cetus Corporation | Method of purifying toxin conjugates using hydrophobic interaction chromatography |
-
1987
- 1987-11-02 GB GB878725606A patent/GB8725606D0/en active Pending
-
1988
- 1988-10-20 NZ NZ226643A patent/NZ226643A/en unknown
- 1988-10-24 AR AR88312284A patent/AR244342A1/es active
- 1988-10-24 CH CH3951/88A patent/CH676248A5/fr not_active IP Right Cessation
- 1988-10-25 NL NL8802617A patent/NL194949C/nl not_active IP Right Cessation
- 1988-10-26 GR GR880100728A patent/GR1000715B/el not_active IP Right Cessation
- 1988-10-28 BE BE8801243A patent/BE1001938A4/fr not_active IP Right Cessation
- 1988-10-28 MY MYPI88001231A patent/MY103445A/en unknown
- 1988-10-28 AU AU24429/88A patent/AU610792B2/en not_active Ceased
- 1988-10-31 PT PT88903A patent/PT88903B/pt not_active IP Right Cessation
- 1988-10-31 SE SE8803930A patent/SE503401C2/sv not_active IP Right Cessation
- 1988-10-31 IT IT8822471A patent/IT1227447B/it active
- 1988-10-31 ES ES8803317A patent/ES2009099A6/es not_active Expired
- 1988-10-31 AT AT0267788A patent/AT396251B/de not_active IP Right Cessation
- 1988-10-31 GB GB8825399A patent/GB2211847B/en not_active Expired - Lifetime
- 1988-11-01 US US07/265,561 patent/US4927755A/en not_active Expired - Lifetime
- 1988-11-01 KR KR1019880014332A patent/KR0134624B1/ko not_active Expired - Fee Related
- 1988-11-01 ZA ZA888180A patent/ZA888180B/xx unknown
- 1988-11-01 DK DK607388A patent/DK607388A/da not_active Application Discontinuation
- 1988-11-01 IE IE329088A patent/IE61610B1/en not_active IP Right Cessation
- 1988-11-01 CA CA000581851A patent/CA1339911C/en not_active Expired - Fee Related
- 1988-11-01 NO NO884865A patent/NO172902C/no unknown
- 1988-11-02 FI FI885045A patent/FI95135C/fi not_active IP Right Cessation
- 1988-11-02 FR FR888814251A patent/FR2622451B1/fr not_active Expired - Lifetime
- 1988-11-02 DE DE3837203A patent/DE3837203A1/de active Granted
- 1988-11-02 JP JP63276359A patent/JPH0712316B2/ja not_active Expired - Fee Related
- 1988-11-02 FR FR888814252A patent/FR2622586B1/fr not_active Expired - Lifetime
- 1988-11-02 TN TNTNSN88113A patent/TNSN88113A1/fr unknown
- 1988-11-18 OA OA59474A patent/OA10206A/fr unknown
-
1992
- 1992-04-14 SG SG407/92A patent/SG40792G/en unknown
- 1992-07-02 HK HK476/92A patent/HK47692A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE4004558C2 (de) | 6-Mercaptopurin- und 2-Amino-6-mercaptopurin-9-ß-D-2',3'-didesoxyribofuranosid, diese enthaltende Mittel, Medikamente und Reagenzien sowie Verfahren zur Herstellung von 2',3'-Didesoxypurinnucleosiden | |
| DE69019640T2 (de) | Verfahren zur herstellung von beta-1,3-glucan in algen. | |
| DE69020276T2 (de) | Amylose-Lysozym-Hybrid, ein Aktivzucker und Verfahren zur Herstellung. | |
| DE1803987A1 (de) | Neues,physiologisch wirksames Peptidolipid und Verfahren zu seiner Herstellung | |
| DE69708862T2 (de) | Derivate von k5 polysaccharid mit hoher, blutgerinnungshemmender wirkung | |
| DE3837203C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2051745A1 (de) | Von Nucleinsäuren stammende Arznei mittel und Verfahren zu ihrer Herstellung | |
| WO1995008555A1 (de) | 2',5'-oligoadenylat-2',3'-cyclophosphate | |
| IE51590B1 (en) | Glycoproteins | |
| DD209392A5 (de) | Verfahren zur herstellung von sterilen zubereitungen hochviskoser loesungen und substanzen | |
| DE2024586C3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE3851022T2 (de) | Verfahren zur Herstellung von verzweigten Fructo-Oligosacchariden. | |
| DE3309271C2 (de) | Verfahren zur Herstellung von immobilisierten Mikroorganismen | |
| DE2930604A1 (de) | Doppelstrangige ribonucleinsaeure, verfahren zu ihrer herstellung und diese enthaltende interferon-induktoren | |
| DE2723451C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2911353C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE3019895C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE69624558T2 (de) | Inhibitor der eindickung der intravaskulären membran | |
| DE3045781A1 (de) | Verfahren zur herstellung eines antitumormittels | |
| DE69722450T2 (de) | Halbsynthetische sulfatierte sulfoaminoheparosane mit hoher antimetastatischer wirkung und reduziertem hämorrhagischem risiko | |
| DE3822406A1 (de) | Verfahren zur herstellung von nucleinsaeurederivaten und verfahren zur herstellung von diese enthaltenden medizinischen zusammensetzungen | |
| DE2227173C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2107148B2 (de) | Verfahren zur Herstellung von Polynucleotide!! durch enzymatische Polymerisation von Nucleosiddiphosphaten | |
| DE2018073A1 (de) | Verfahren zur Gewinnung makromoleVularer Amylose | |
| DE1617279A1 (de) | Verfahren zur Herstellung pharmazeutischer Praeparate zur Verhinderung der Bildung von Blutgerinnseln |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |